BridgeBio Pharma: Wells Fargo maintains a 'Overweight' Rating, The Target Price is $88

Wells Fargo maintains 'Overweight' rating on BridgeBio Pharma(BBIO).

The target price is $88, compare with $84 previously.

[Recent Rating]

Date	Agency	Change	Rating	Rating （previously）	Target Price	Target Price（previously）
2026-01-20	Wells Fargo	Maintains	Overweight	Overweight	$88	$84
2026-01-08	Truist Securities	Maintains	Buy	Buy	$86	$80
2026-01-06	Morgan Stanley	Initiates Coverage On	Overweight	--	$96	$--

[Recent Earning Results] Bridgebio Pharma posted the Q3 of its 2025 financial results on 10/29/2025, reporting total revenue of USD 347.90 million in the first three quarters, up 61.05% from USD 216.02 million year over year, reporting net income of USD -538.30 million in the first three quarters, expanding 95.07% from USD -275.96 million year over year.

[Company Profile] BridgeBio Pharma, Inc. was formed in the Delaware on May 17, 2019. The company is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers.